Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis

Abstract

Sarcoidosis is an inflammatory disease characterized by the formation of noncaseating granulomas in one or multiple organ systems. Sarcoidosis most commonly affects the lungs and lymph nodes but can affect nearly any organ including the heart. There are no molecularly targeted therapies approved by the US Food and Drug Administration for the treatment of sarcoidosis, and prednisone, which is approved for pulmonary sarcoidosis, remains a mainstay of therapy. Cutaneous lesions have been described in approximately 25% to 33% of patients with sarcoidosis, and treatment options are limited; there are no US Food and Drug Administration–approved treatments for cutaneous sarcoidosis.